Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
Wang K et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2024
Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.
Zhang L et al.
Molecular Oncology, 2022
35971249 (PubMed )
Supplement: MOL2-16-3689-s005.xlsx › Table_S3
The next tier of EGFR resistance mutations in lung cancer.
Tumbrink HL et al.
Oncogene, 2021
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.
Fairclough SR et al.
Experimental Hematology & Oncology, 2019
Select a paper to view details